Ribofuranose-based GalNAc-conjugated siRNA enhances the liver-targeted delivery and elicits robust RNAi-mediated gene silencing
The N-acetylgalactosamine (GalNAc)-conjugate delivery platform has emerged as a pivotal enabling technology for the clinical translation of oligonucleotide therapeutics. The development of GalNAc-conjugated small interfering RNA (siRNA) therapeutics has been significantly advanced through structural...
Збережено в:
| Автори: | , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Elsevier
2026-03-01
|
| Серія: | Molecular Therapy: Nucleic Acids |
| Предмети: | |
| Онлайн доступ: | http://www.sciencedirect.com/science/article/pii/S2162253125003555 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|